title: Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin.
abstract: Here we presented a 60-year-old Taiwanese man with advanced gastrointestinal stromal tumor. Disease progression was noted during imatinib treatment. Surgical resection was done and mutation analysis of KIT gene in all the resected tumors revealed deletion mutations of codons 558-565 in exon 11, whereas a missense mutation was also identified at codon 822 in exon 17 in one resected tumor. Patient's disease was refractory to escalating dose of imatinib and dasatinb. Surprisingly, combination of imatinib with pegylated liposomal doxorubicin produced a substantial response and resulted in a 5-month progression free period for this imatinib-resistant gastrointestinal stromal tumor.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
authors.forename: Yao-Yu
authors.initials: YY
authors.lastname: Hsieh
authors.forename: Chueh-Chuan
authors.initials: CC
authors.lastname: Yen
authors.forename: Chun-Nan
authors.initials: CN
authors.lastname: Yeh
authors.forename: Chin-Yuan
authors.initials: CY
authors.lastname: Tzen
authors.forename: Jin-Hwang
authors.initials: JH
authors.lastname: Liu
authors.forename: Hui-Ju
authors.initials: HJ
authors.lastname: Lee
authors.forename: Hao-Wei
authors.initials: HW
authors.lastname: Teng
authors.forename: Cheng-Hwai
authors.initials: CH
authors.lastname: Tzeng
authors.forename: Tzeon-Jye
authors.initials: TJ
authors.lastname: Chiou
authors.forename: Ta-Chung
authors.initials: TC
authors.lastname: Chao
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage; D016879:Salvage Therapy
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit